1 |
Tsuda N Murayama K Ishida H Matsunaga K Komiya S Itoh K Yamada A Expression ofa newly defined tumor-rejection antigen SART3 in musculoskeletal tumorsand induction of HLA class I-restricted cytotoxic T lymphocytes bySART3-derived peptidesJ Orthop Res 2001 19(3)346351
|
2 |
Catros-Quemener V Bouet F Genetet N Antitumor immunity and cellular cancer therapiesMed Sci (Paris) 2003 19(1)4353
|
3 |
Nicodemus C F Smith L M Schultes B C Role of monoclonal antibodies in tumor-specific immunity.Expert Opin Biol Ther 2007 7(3)331343
|
4 |
Huang F M Zheng Q X Lv B Bao T Z Cloning andExpression of hB7-1/Sart3 Fusion ProteinHuazhong Keji Daxue Xuebao (Medical edition) 2004 33(2)165168(in Chinese)
|
5 |
Uenaka A Nakayama E Analysis of tumor rejectionantigen peptides recognized by specific CTLNippon Rinsho 1996 54(1)242249(in Japanese)
|
6 |
Yang D Nakao M Shichijo S Sasatomi T Takasu H Matsumoto H Mori K Hayashi A Yamana H Shirouzu K Itoh K Identificationof a gene coding for a protein possessing shared tumor epitopes capableof inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patientsCancer Res 1999 59(16)40564063
|
7 |
Nagamori M Kawaguchi S Murakami M Wada T Nagoya S Yamashita T Inobe M Uede T Intrinsic and extrinsic manipulation of B7/CTLA-4 interactionfor induction of anti-tumor immunity against osteosarcoma cellsAnticancer Res 2002 22(6A)32233227
|
8 |
Harada K Yamada A Mine T Kawagoe N Takasu H Itoh K Mousehomologue of the human SART3 gene encoding tumor-rejection antigenJpn J Cancer Res 2000 91(2)239247
|
9 |
Hodi F S Dranoff G Combinatorial cancer immunotherapyAdv Immunol 2006 90341368
|
10 |
Palena C Abrams S I Schlom J Hodge J W Cancer vaccines:preclinical studies and novel strategiesAdv Cancer Res 2006 95115145
|
11 |
Niiya F Nishizaka S Matsunaga K Koufuji K Mori M Katai H Yamana H Itoh K Expression of SART3 tumor-rejection antigen in gastriccancersJpn J Cancer Res 2000 91(3)337342
|
12 |
Kawagoe N Shintaku I Yutani S Etoh H Matuoka K Noda S Itoh K Expression of the SART3 tumorrejection antigen in renal cell carcinomaJ Urol 2000 164(6)20902095
|
13 |
Suefuji Y Sasatomi T Shichijo S Nakagawa S Deguchi H Koga T Kameyama T Itoh K Expression of SART3 antigen and induction of CTLs by SART3-derivedpeptides in breast cancer patientsBr JCancer 2001 84(7)915919
|
14 |
Fukuda K Expressionof the SART3 antigens in oral cancersKurumeMed J 2001 48(1)5558
|
15 |
Hersh E M Stopeck A T Advances in the biologicaltherapy and gene therapy of malignant diseaseClin Cancer Res 1997 3(12 Pt 2)26232629
|
16 |
Moiseyenko V Imyanitov E Danilova A Danilov A Baldueva I Cell technologies in immunotherapy of cancerAdv Exp Med Biol 2007 601387393
|
17 |
Dzierzbicka K Kolodziejczyk A M Adjuvants--essential componentsof new generation vaccinesPostepy Biochem 2006 52(2)204211
|
18 |
Jager E Jager D Knuth A Antigen-specific immunotherapy and cancer vaccinesInt J Cancer 2003 106(6)817820
|
19 |
Muehlbauer P M Schwartzentruber DJ Cancer vaccinesSemin Oncol Nurs 2003 19(3)206216
|
20 |
Soltani M S Belghith Z Gacem H Bchir A Value of vaccinationdata analysis at the district levelEastMediterr Health J 1999 5(3)565571
|